Varian Works with Sify Technologies to Host Data Remotely Across CTSI Network of Cancer Centers in India

In the first project of its kind outside the United States, Varian Medical Systems (NYSE: VAR) is working with Sify Technologies to provide software-as-a-service (SaaS) to radiotherapy centers across India. The innovative service, which hosts oncology information and treatment planning software in the cloud and allows clinical teams to focus on treating patients, is being implemented as part of a multi-million dollar investment in treatment equipment and software across Cancer Treatment Services International CTSI's network of cancer hospitals in India and South Asia.
"CTSI is rapidly expanding its network across the region, and the cloud-hosted solution enables us to focus on delivering high quality, consistent care to our patients," said Vishal Bali, CTSI's Chairman. "Our flagship Hyderabad facility, operated under the name American Oncology Institute (AOI), is the first in India to implement this innovative solution for remote software hosting and better connectivity with our clinicians.  These unique capabilities differentiate our hospitals and facilitate the use of evidence-based protocols and tools, such as cutting-edge treatment planning technologies, across the AOI network."
In line with a two-year implementation plan, the first three sites – including Hyderabad – are already clinical and other CTSI centers in India will follow suit in the coming months. It is the first SaaS project of its kind for Varian outside North America and forms part of a larger order from CTSI for 12 advanced Varian linear accelerators – including 10 top-of-the-range TrueBeam™ systems – to be installed at CTSI hospitals across the region.
Joe Nicholas, co-founder and executive director of CTSI, said, "We are delighted with how this project has come to fruition. It has been delivered on time and the result is very impressive. Our clinical teams now have access to a robust centralized electronic system and are no longer working in isolation."
"With a unique SaaS model such as this CTSI subscribes to the software, as part of the service packages provided by Sify that include all required IT infrastructure and hosting, rather than buying it," says Steve Laws, Varian's head of software sales in the EMEIA region. "It makes sense for them because as well as offering economies of scale, it means their clinical teams are freed up to focus on treating cancer patients."
Raju Vegesna, chairman of Chennai-based Sify Technologies, added, "Together with Varian, we wanted to build a solution that would eliminate many of the problems facing Indian hospitals, which tend to work in isolation. We have come up with a common platform stored in a private cloud, through which all practitioners in the network have instant access to all data. With this model, all radiation planning can be done remotely in a process that has been streamlined from disease detection to treatment. The local doctors have continuous peer group collaboration and knowledge sharing."
"With private storage, we never run short of space and no patient data is eliminated," he added. "We firmly believe this is how oncology treatment will be handled going forward in India and across South-East Asia. It is a complete break with the past and offers huge benefits. And if we can do this here, in India, we can do it anywhere in the world."    
In the first quarter of its current fiscal year, Varian announced it had booked $18 million of a $35 million order from CTSI for the India project. "This is our first software-as-a-service project in the region and demonstrates our ability to meet the growing need from customers for cloud-hosted software solutions," said Varian CEO Dow Wilson.
About Varian Medical Systems Varian Medical Systems focuses energy on saving lives and is the world's leading manufacturer of medical devices and software for treating and managing cancer. Headquartered in Palo Alto, California, Varian employs approximately 6,400 people at sites around the world. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.
About Sify Technologies Across 1400 cities in India, more than 9000 Enterprises access Sify's ICT services that's focused on the Data Center and Cloud platform and connected through a pan-India MPLS capable network. The services run the full gamut from Telecom connectivity services to Data Center transformation services along with Application and Security Services on the same infrastructure making it a truly converged ICT solutions and services provider in India. Sify also builds products that interface with multiple services in the ICT space; either built in-house or collaboratively with the best-of-breed solution providers. Sify Technologies and www.sifycorp.com are registered trademarks of Sify Technologies Limited.
About CTSI CTSI is a leading provider of comprehensive treatment for cancer patients in emerging and frontier markets. Founded by physicians and businessmen with substantial experience in the development, operation and networking of cancer services, CTSI provides innovative and technologically-advanced treatment solutions through an IT-based model that allows integration and centralization of core services. The company began international operations at its flagship cancer hospital in Hyderabad, India, and is rapidly expanding a network of cancer hospitals across India and South Asia. For more information visit www.cancertreatmentservices.com.

Source:http://www.prnewswire.co.in/news-releases/varian-works-with-sify-technologies-to-host-data-remotely-across-ctsi-network-of-cancer-centers-in-india-629864363.html

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that BMTP
Read more